CVRx, Inc. (CVRX)
NASDAQ: CVRX · Real-Time Price · USD
7.86
-0.39 (-4.73%)
At close: Mar 9, 2026, 4:00 PM EDT
8.01
+0.15 (1.91%)
After-hours: Mar 9, 2026, 4:39 PM EDT
CVRx, Inc. Revenue
In the year 2025, CVRx, Inc. had annual revenue of $56.65M with 10.45% growth. CVRx, Inc. had revenue of $16.02M in the quarter ending December 31, 2025, with 4.45% growth.
Revenue (ttm)
$56.65M
Revenue Growth
+10.45%
P/S Ratio
3.65
Revenue / Employee
$254,040
Employees
223
Market Cap
206.81M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| InfuSystem Holdings | 143.44M |
| Quanterix | 138.90M |
| Owlet | 105.70M |
| Sight Sciences | 77.36M |
| Electromed | 68.86M |
| 908 Devices | 56.20M |
| SANUWAVE Health | 41.28M |
| Senseonics Holdings | 35.26M |
CVRX News
- 7 days ago - CVRx Announces Late-Breaking Data and Scientific Presentations Highlighting Barostim Outcomes at the THT 2026 Annual Meeting - GlobeNewsWire
- 24 days ago - CVRx, Inc. (CVRX) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - CVRx to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call on February 12, 2026 - GlobeNewsWire
- 6 weeks ago - CVRx Kicks Off One Of The Largest Heart Device Trials In History - Benzinga
- 6 weeks ago - CVRx Announces Initiation of BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population - GlobeNewsWire
- 7 weeks ago - CVRx, Inc. (CVRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2025 Financial Results and Issues Fiscal 2026 Guidance - GlobeNewsWire
- 2 months ago - CVRx Announces Implementation of New Category I CPT Codes for Barostim Therapy - GlobeNewsWire